target menu
 

Boer, Monique den

  Back to List

 

Monique L. den Boer obtained her MSc degree in Biology, specialism Medical Biology, at the University of Utrecht in 1993 (cum laude). In 1998 she obtained her PhD degree at the faculty of Medicine of the ‘Vrije Universiteit’ in Amsterdam for her research on causes of resistance to anthracyclines in children with acute leukemia. In that same year she was awarded the Dr. de Vaan prize for excellent research in pediatric oncology. She received a fellowship of the International Union against Cancer (UICC) to study defects in the apoptosis pathway of leukemic cells at the Children’s University Hospital of Ulm, Germany. In 1999 she was appointed as senior scientist to set up a research laboratory of pediatric oncology at the Erasmus MC-Sophia Children’s Hospital, Rotterdam. Two years later she became head of the research laboratory (which currently harbors ~45 employees) and tenured-track staff member of the department of Pediatric Oncology/Hematology. In 2005 she became associate professor (UHD) in molecular pediatric oncology at the Erasmus MC. In 2006 she obtained an NWO-VIDI grant for studying microRNAs in acute leukemia. 2008 she was awarded with the Translational Research award of the international pediatric oncology society (SIOP) for her discovery of a novel subtype of pediatric leukemia.

Monique den Boer is principal investigator of a research group consisting of ~15 PhD students, post-docs, clinical fellows, research technicians and bio-informaticians/-statisticians. Her research program aims to find new molecular markers and drugable targets for children with acute leukemia in order to improve the risk-group classification at initial diagnosis and treatment outcome of these patients. This translational research program focuses amongst others on the role of microRNAs, genetic abnormalities, abnormal gene expression patterns and protein activities (e.g. phosphorylation status) to the development of leukemia as well as resistance towards chemotherapeutic drugs. Newly identified molecular markers and/or drugable targets are further evaluated for their use in targeted therapy. The final goal is to improve treatment results of children with acute leukemia by using better diagnostics at the presentation of the disease as well as by applying targeted drugs that most effectively kill leukemic cells with the least side-effects.

 

Publications

Den Boer ML, Van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JGCAM, Peters TCJM, Van Zutven LJCM, Beverloo HB, Van der Spek PJ, Escherich G, Horstmann MA, Janka-Schaub GE, Kamps WA, Evans WE, Pieters R
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
Lancet Oncol 10, 125-134 (2009)

Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJC, Evans WE, Pieters R, Den Boer, ML
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells
Blood 113, 2014-2021 (2009)

Schotte D, Chau JCK, Sylvester G, Liu G, Chen C, Van der Velden VHJ, Broekhuis MJC, Peters TCJM, Pieters R and Den Boer ML
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia
Leukemia 23, 313-322 (2009)

Appel IM, Kazemier KM, Boos J, Lanvers C, Huijmans J, Veerman AJ, van Wering E, den Boer ML, Pieters R
Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study
Leukemia 22, 1665-1679 (2008)

Tissing WJ, Den Boer ML, Meijerink JP, Menezes RX, Swagemakers S, van der Spek PJ, Sallan SE, Armstrong SA, Pieters R
Genome-wide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells
Blood 109, 3929-3935 (2007)

Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R, Golub TR, Armstrong SA
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance
Cancer Cell 10, 331-342 (2006)

Holleman A, Den Boer ML, Menezes RX, Cheok MH, Cheng C, Kazemier KM, Janka-Schaub GE, Gobel U, Graubner UB, Evans WE, Pieters R.
The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia.
Blood 107, 769-776 (2006)

Holleman A, Cheok MH, Den Boer ML, Yang W, Veerman AJP, Kazemier KM, Pei P, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R and Evans WE.
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
N Eng J Med, 351:533-542 (2004)

Den Boer ML, Harms DO, Pieters R, Kazemier KM, Göbel U, Körholz D, Graubner U, Haas RJ, Jorch N, Spaar HJ, Kaspers GJL, Kamps WA, Van der Does-van den Berg A, Van Wering ER, Veerman AJP and Janka-Schaub GE.
Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
J Clin Oncol 21, 3262-3268 (2003)

Armstrong SA, Staunton JE, Silverman LB, Pieters R, Den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Nature Genetics 30, 41-47 (2002)